Physician profile
Brian N Mathews
NPI 1841210713
$9,994.10
in general payments reported to CMS, 2019-2025
66 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $844 · 2021: $555 · 2022: $1,346 · 2023: $1,517 · 2024: $2,178 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,465 · Grant: $501 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,465.30 |
| Grant | $500.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $747.73 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $736.02 | 2019-2025 | |
| Abbvie INC. | $671.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $650.61 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Seagen INC. | $638.68 | 2020-2023 | Tukysa, Padcev, Adcetris |
| Pfizer INC. | $585.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $528.09 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Welch Allyn | $432.31 | 2021 | |
| Janssen Biotech, INC. | $424.79 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Amgen INC. | $351.29 | 2019-2023 | Kyprolis |
| Eisai INC. | $344.36 | 2019-2024 | |
| Astellas Pharma US INC | $335.86 | 2019-2024 | Xtandi |
| Genzyme Corporation | $295.49 | 2019-2024 | |
| Lilly USA, LLC | $217.02 | 2019-2025 | Jaypirca, Verzenio |
| Celgene Corporation | $206.23 | 2019-2024 | Pomalyst, Reblozyl |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.